OSOscar Mauricio Espitia Segura

Oscar Mauricio Espitia Segura

*This is an algorithmically generated author record based on publicly available information.

Oscar Mauricio Espitia Segura has a total of 128 co-authors. Here are the top co-authors by number of shared publications:

  • Nathalia Elena Penagos Vargas

    Qualitative and Quantitative Research Network in Neuropediatrics (RICCNeP), Bogotá, Colombia; Neuropediatrics Division, HOMI Fundación Hospital Pediátrico La Misericordia, Bogotá, Colombia

    4 shared publications
  • Alessandra Marques Pereira

    Hospital Moinhos de Vento, Porto Alegre, Brazil

    3 shared publications
  • Angélica Arteaga Arteaga

    Clínica León XIII, Medellín, Colombia

    3 shared publications
  • Carolina Amoretti

    Hospital Universitario Professor Edgar Santos, Salvador, Brazil

    3 shared publications
  • Consuelo Durand

    Laboratorio de Neuroquimica Dr. N.A. Chamoles, Ciudad Autónoma de Buenos Aires, Argentina

    3 shared publications
  • David Montoya Ossa

    Qualitative and Quantitative Research Network in Neuropediatrics (RICCNeP), Bogotá, Colombia; Neuropediatrics Division, HOMI Fundación Hospital Pediátrico La Misericordia, Bogotá, Colombia

    3 shared publications

Latest Publications

  • Complications of acute sinusitis and acute otitis media: before, during, and after the COVID-19 pandemic in the pediatric population

    by Natalia María Ibáñez Méndez, Oscar Mauricio Espitia Segura, Javier Alfonso Aguilar Mejía, Diego Mauricio Galvis Trujillo, Yenny Carolina Zuñiga Zambrano, Luis Felipe Romero Moreno

  • Intravenous Lacosamide in Pediatric Epilepsy: Experience From a High-Complexity Center in Bogotá, Colombia

    by Nathalia Elena Penagos-Vargas, David Montoya-Ossa, Oscar Mauricio Espitia Segura, Juan David Farfán-Albarracín

  • Intravenous lacosamide for pediatric status epilepticus and seizure clusters: A single-center observational study

    by Nathalia Elena Penagos Vargas, David Montoya Ossa, Oscar Mauricio Espitia Segura, Juan David Farfán-Albarracín

  • Open Access

    Signos de alarma para el diagnóstico de la deficiencia de L-aminoácido aromático descarboxilasa

    by Marvid Sol Duarte Moreno, Sandra Milena Castellar Leones, Sandra Yaneth Ospina Lagos, Jorge Luis Ramón Gómez, Edicson Ruiz Ospina, Carolina Toro, Ana María Zarante Bahamón, Adolfo Enrique Álvarez Montañez, Hernán Amartino, Diana Carol Benítez Ramírez, et al.

    Introducción. La deficiencia de L-aminoácido aromático descarboxilasa (AADC) es un trastorno metabólico genético causado por variantes patogénicas en el gen de la Dopa Descarboxilasa que afectan la biosíntesis de dopamina, siendo esta última precursora de norepinefrina y epinefrina. Su baja frecuencia y su similitud clínica con otras afecciones como la parálisis cerebral o la epilepsia retrasan el diagnóstico. La detección temprana de este trastorno es clave para un manejo oportuno. Objetivo. Establecer recomendaciones claras y adaptadas al contexto local que faciliten la detección oportuna de signos de alarma para el diagnóstico de la deficiencia de AADC y mejoren la atención integral de los pacientes con esta condición. Métodos. Se llevó a cabo un position statement en el que participaron 23 profesionales de la salud con experiencia en deficiencia de AADC cuya elaboración siguió un proceso sistemático con el fin de asegurar rigurosidad. Se elaboraron algoritmos diagnósticos y puntos de buena práctica clínica para cada nivel. Resultados. El panel acordó recomendaciones por nivel de atención y grupo etario (3 meses a 2 años, 2 a 5 años, 5 a 12 años). Nivel 1 (médicos generales, enfermeros, terapeutas físicos y gestores de salud): identificación de retraso o regresión del neurodesarrollo. Nivel 2 (pediatras): búsqueda etiológica en parálisis cerebral y reconocimiento de movimientos anormales. Nivel 3 (neuropediatras, genetistas y fisiatras): clasificación de movimientos y diagnóstico de errores innatos del metabolismo. Conclusiones. Este position statement ofrece recomendaciones y algoritmos adaptados localmente que facilitan la identificación de signos de alarma y agilizan el diagnóstico de la deficiencia de AADC, lo que ayuda a mejorar el pronóstico y la calidad de vida de los pacientes.

  • Open Access

    Presymptomatic Versus Late Cerliponase Alfa Therapy in CLN2 Disease: Sibling Case Report

    by Oscar Mauricio Espitia Segura, María Camila Villalba-Guerrero, David Montoya Ossa, Ricardo Andrés Naranjo Flórez

    Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rapidly progressive neurodegenerative disorder caused by TPP1 deficiency. Intracerebroventricular cerliponase alfa slows motor-language decline, although outcomes vary with disease stage at treatment initiation. Intrafamilial comparisons remain scarce, particularly in Latin America. We report two Colombian siblings carrying identical compound heterozygous TPP1 variants (c.622C>T [p.Arg208*] and c.887-10A>G) with markedly reduced enzyme activity. The older brother began enzyme replacement therapy (ERT) at age 11 with advanced neurologic impairment; whereas his sister started presymptomatically at age 3 following cascade testing. Clinical scales, neuroimaging, and cerebrospinal fluid neurofilament light (CSF NfL) levels were analyzed during 5-6 years of treatment. Before diagnosis, the brother developed language regression, ataxia, epilepsy, and visual decline. After ERT initiation, no further major motor milestone loss ocurred, seizures remained controlled, and severe disability persisted; CSF NfL decreased from 1,334 to 504 pg/mL during maintenance. His sister remained neurologically intact at age 9, with preserved motor-language function, normal MRI, and maintenance-phase CSF NfL levels of 359-531 pg/mL. These divergent intrafamilial trajectories support early TPP1 testing and prompt cascade screening in at-risk siblings, although longer follow-up is required to establish the durability of presymptomatic benefit.

  • Open Access

    Disability, poverty and health-service accessibility in the context of the COVID-19 pandemic: a population-based repeated cross-sectional study in Colombia

    by Oscar Mauricio Espitia Segura, Monica Pinilla-Roncancio

    Objectives In Colombia, 4.3% of the population 5 years or older lives with a disability. They face higher levels of poverty and social exclusion compared with persons without disabilities. This article aims to understand the factors associated with access to preventative and curative health services for people with disabilities in Colombia. Additionally, it explores whether access to health services for people with disabilities changed during the COVID-19 pandemic. Design This is a population-based repeated cross-sectional study. Setting This study took place in Colombia, from 2018 to 2021. Data sources and participants National Quality of Life Survey datasets in Colombia from 2018 to 2021, including people 5 years or older, were reviewed. People were classified into three groups: person with any disability, person with multiple disabilities and person without disabilities. Primary and secondary outcome measures A multinomial regression model was used to calculate the probability of access to preventative services during the previous year in four categories: general practitioner (GP) and dentist, GP only, dentist only and no consultation. A logistic model for curative consultations with and without hospitalisation in people who reported having a health problem. Results People with disabilities demanded more preventative health services, except for dental services, compared with people without disabilities. Similarly, they experienced more health problems and demanded more curative services than people without disabilities, except during the year 2020, when no significant differences were found between people with and without disabilities. For people with disabilities, poverty was not associated with a lower likelihood of consultation, except for preventative dental consultations, which were significantly lower for poor people with disabilities. In addition, the subsidised insurance regimen was identified as an important variable in the utilisation of healthcare in Colombia. Conclusion People with disabilities in Colombia demand more health services compared with people without disabilities. Despite being in a worse condition according to various socioeconomic indicators, few factors affect their demand for healthcare services. The COVID-19 pandemic was associated with a significant reduction in the probability of access to outpatient treatment services during 2020 for people with disabilities. Longitudinal studies and comparison with other Latin American countries are recommended.


  • Open Access

    Panorama de la fenilcetonuria en Colombia

    by Ana Maria Zarante Bahamón, Sandra Milena Navarro Marroquín, Juan Carlos Prieto, Lissete Cabarcas Castro, Marvid Sol Duarte Moreno, Oscar Mauricio Espitia Segura, Ignacio Zarante, Luz Helena Castaño Torres, Sandra Catalina Mesa Restrepo, Carolina Baquero, et al.

    Antecedentes: La fenilcetonuria (PKU), es un error innato del metabolismo secundario a un defecto del metabolismo hepático de la fenilalanina. Su acumulación afecta principalmente el sistema nervioso central, generando discapacidad cognitiva y alteración comportamental importante. Tema: El diagnóstico temprano, mediante el cribado neonatal, permite modificar la historia natural de la enfermedad y brindar un adecuado asesoramiento genético. Conclusión: Los autores damos una revisión al estado actual de la patología y el tamizaje neonatal en Colombia, así como los retos en el seguimiento y manejo de estos pacientes diagnosticados temprana o tardíamente.

  • Headache and Other Factors Modifying Cerebrospinal Fluid Opening Pressure in Pediatric Patients

    by Oscar M. Espitia Segura, Ana M. Bedoya Morales, Cristina L. Ramírez-Sierra, Juan D. Farfán-Albarracín, Sofy H. Pérez Cárdenas, Jennifer J. Guzmán-Porras, Luisa F. López Mora, Mateo H. Ramírez Salazar, Leydi A. Ceballos Inga, María C. Rueda Rodríguez, et al.

    Cerebrospinal fluid opening pressure values are associated with various neurologic diseases; however, numerous factors can modify this measurement. This study aims to describe factors related to modifications in opening pressure measurements in pediatric patients. Methods: A retrospective analysis of lumbar punctures in pediatric patients conducted by the neuropediatrics group with institutional standardization. Bivariate and linear regression analyses were performed to determine the association between opening pressure and variables included in the study. Results: 544 events, median age 107 months, median opening pressure 19.7 cm H2O. Bivariate analysis found no association with medication use; anesthetics that increased opening pressure were remifentanil ( P = .02) and propofol ( P = .05), along with a positive linear correlation between opening pressure and age ( P < .0001). Multiple linear regression analysis revealed that age, BMI, male gender, and remifentanil use were associated with an increase in opening pressure, whereas corticosteroid withdrawal was associated with a reduction in opening pressure. There is an interaction between age and headache, with an association with increased opening pressure up to around 140 months. Conclusion: This study identifies factors associated with changes in opening pressure, crucial for estimating normal opening pressure values in children. Headaches, anesthetic use, and corticosteroid withdrawal are confirmed as significant factors.


  • Corrigendum to “Classic and atypical late infantile neuronal ceroid lipofuscinosis in Latin America: Clinical and genetic aspects, and treatment outcome with cerliponase alfa.” [Molecular Genetics and Metabolism ReportsVolume 38 (2024) 101060]

    by Norberto Guelbert, Oscar Mauricio Espitia Segura, Carolina Amoretti, Angélica Arteaga Arteaga, Nora Graciela Atanacio, Natacha Sabrina Bazan, Ellaine Doris Fernandes Carvalho, Maria Denise Fernandes Carvalho de Andrade, Inés María Denzler, Consuelo Durand, et al.


  • Open Access

    Classic and Atypical Late Infantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and Genetic Aspects, and Treatment Outcome with Cerliponase Alfa

    by Norberto Guelbert, Oscar Mauricio Espitia Segura, Carolina Amoretti, Angélica Arteaga Arteaga, Nora Graciela Atanacio, Sabrina Bazan Natacha, Ellaine Doris Fernandes Carvalho, Maria Denise Fernandes Carvalho de Andrade, Inés María Denzler, Consuelo Durand, et al.